Conatus Pharmaceuticals (CNAT) – StreetInsider.com Reports
-
Histogen Granted FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia
-
Pre-Open Stock Movers 01/29: (LEE) (LB) (GE) Higher (BHVN) (EXTR) (XLNX) Lower (more...)
-
After-Hours Stock Movers 01/28: (CNAT) (MTSI) (ARAY) Higher; (XLNX) (BHVN) (CHRW) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) annouunces Histogen will merge with its wholly-owned subsidiary in an all-stock transaction
-
Conatus Pharmaceuticals (CNAT) Halted, News Pending
-
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4:35 pm
-
Conatus Pharmaceuticals (CNAT) commences restructuring plan that includes reducing staff by approximately 40%
-
Conatus Pharmaceuticals (CNAT) Halted, News Pending
-
Exclusive: Apollo Global makes offer for France's Coface: sources
-
After-Hours Movers 06/24: (ALDX) (GNFT) (USNA) Higher; (CNAT) (GMDA) (KRYS) (more...)
-
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4:35 pm ET
-
Conatus Pharmaceuticals (CNAT) to Explore Strategic Alternatives, Implement Restructuring Plan
-
Conatus Pharmaceuticals (CNAT) ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Didn't Meet Primary Endpoint
-
Conatus Pharmaceuticals (CNAT) Halted, News Pending
-
UPDATE: Roth Capital Downgrades Conatus Pharmaceuticals (CNAT) to Neutral
-
Pre-Open Stock Movers 03/22: (HIBB) (SRNE) (LITE) Higher; (CNAT) (ZUO) (CAL) Lower (more...)
-
H.C. Wainwright Downgrades Conatus Pharmaceuticals (CNAT) to Neutral
-
SunTrust Downgrades Conatus Pharmaceuticals (CNAT) to Hold
-
After-Hours Movers 03/21: (AMRN) Higher; (CNAT) (ZUO) (CAL) (more...)
-
Conatus (CNAT) falls 45% after announcing emricasan did not have the desired effect in earlier-stage NASH fibrosis patients
-
Conatus Pharmaceuticals (CNAT) Reports Top-Line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
-
Conatus Pharmaceuticals (CNAT) Reports Complete Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
-
Conatus Pharmaceuticals (CNAT) Reports Publication of Expanded Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
-
Pre-Open Movers 12/06: (TST) (MIK) (SHPG) Higher; (CNAT) (NPTN) (HOME) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
-
Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer
-
Conatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary Endpoint
-
Stifel Downgrades Conatus Pharmaceuticals (CNAT) to Hold
-
Conatus Pharmaceuticals (CNAT) Announces Three Accepted Abstracts for AASLD
-
Conatus Pharmaceuticals (CNAT) Announces Complete Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis & Severe Portal Hypertension
-
Conatus Pharmaceuticals (CNAT) Highlights Publication of Results from both In-Vitro & In-Vivo Studies of IDN-7314 Pan-caspase Inhibitor
-
Pre-Open Movers 04/05: (CHFS) (FNSR) (HRTX) Higher; (CNAT) (CHECK) (CONN) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) PT Lowered to $20 at SunTrust Robinson Humphrey
-
After-Hours Stock Movers 04/04: (FB) (AMD) Higher; (CNAT) (CHEK) (OLLI) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4:35 pm ET
-
Conatus Pharmaceuticals (CNAT) Phase 2b POLT-HCV-SVR Clinical Trial Doesn't Meet Primary Endpoint
-
Conatus Pharmaceuticals (CNAT) Halted, News Pending
-
Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 2c
-
Oppenheimer Starts Conatus Pharmaceuticals (CNAT) at Outperform
-
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy, 'High Ambitions, High Reward'
-
Conatus Pharmaceuticals (CNAT) Misses Q3 EPS by 8c
-
Conatus Pharmaceuticals (CNAT) Announces Poster Presentation at AASLD
-
Pre-Open Movers 10/19: (ADHD) (RWLK) (BLFS) Higher; (OPTT) (ESTE) (EBAY) Lower (more...)
-
After-Hours Stock Movers 10/18: (LLNW) (ADBE) (GILD) Higher; (OPTT) (ESTE) (EBAY) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC
-
Seaport Global Securities Starts Conatus Pharmaceuticals (CNAT) at Buy
-
Conatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO and CFO
-
Conatus Pharmaceuticals (CNAT) Misses Q2 EPS by 2c
-
Pre-Open Movers 06/26: (STOR) (PTLA) (P) Higher; (NEOT) (MTNB) (GRUB) Lower (more...)
-
Conatus Pharmaceuticals (CNAT) Gains FDA Orphan Drug Designation for IDN-7314
Back to CNAT Stock Lookup